IL-2-induced IL-5 synthesis, but not proliferation, of human CD4+ T cells is suppressed by FK506. 1997

A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
Department of Medicine, Faculty of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Japan.

Regulation of T cell IL-5 synthesis was investigated using human Th cell clones. Immunosuppressant FK506 suppressed IL-5 synthesis of T cells activated through TCR in a dose-dependent manner. IL-5 gene transcription and protein synthesis were also induced in the same T cell clones upon stimulation with IL-2 and were suppressed by FK506 in a dose response similar to that induced by TCR stimulation. In contrast to TCR stimulation, neither activating protein-1, nuclear factor-AT (NF-AT), nor NF-kappaB binding activity was significantly up-regulated by IL-2 stimulation. Human IL-5 promoter/enhancer-luciferase gene construct transfected to T cell clones was transcribed upon either TCR or IL-2 stimulation and was clearly down-regulated by FK506, indicating that the approximately 500-bp human IL-5 gene segment located 5' upstream of the coding region contained FK506-sensitive enhancer elements. Our present findings clearly indicate that FK506-sensitive signaling molecules are involved in T cell IL-5 production induced by both TCR and IL-2 stimulation and suggest that IL-2 receptor signal leading to IL-5 gene transcription is transduced by a unique FK506-sensitive pathway other than the Ca2+-dependent signal transduction pathway, such as the calcineurin-NF-AT system.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002999 Clone Cells A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed) Clones,Cell, Clone,Cells, Clone,Clone,Clone Cell
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015848 Interleukin-5 A cytokine that promotes differentiation and activation of EOSINOPHILS. It also triggers activated B-LYMPHOCYTES to differentiate into IMMUNOGLOBULIN-secreting cells. B-Cell Growth Factor-II,Eosinophil Differentiation Factor,IL-5,T-Cell Replacing Factor,BCGF-II,Differentiation Factor, Eosinophil,IL5,T-Cell-Replacing Factor,B Cell Growth Factor II,Interleukin 5,Replacing Factor, T-Cell,T Cell Replacing Factor
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous

Related Publications

A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
August 2017, Journal of leukocyte biology,
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
June 1991, Journal of immunology (Baltimore, Md. : 1950),
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
January 1989, Immunology letters,
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
September 1985, Journal of immunology (Baltimore, Md. : 1950),
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
December 1994, Journal of immunology (Baltimore, Md. : 1950),
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
February 1999, Journal of immunology (Baltimore, Md. : 1950),
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
March 2003, European journal of immunology,
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
March 1995, Journal of clinical immunology,
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
September 2004, Journal of immunology (Baltimore, Md. : 1950),
A Mori, and M Suko, and O Kaminuma, and S Inoue, and T Ohmura, and A Hoshino, and Y Asakura, and E Terada, and K Miyazawa, and C Nosaka, and Y Okumura, and K Ito, and H Okudaira
October 1990, European journal of immunology,
Copied contents to your clipboard!